PC
ARQT icon

Polar Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Polar Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$10.3M Sell
350,000
-100,000
-22% -$2.67M 0.08% 181
2020
Q2 		$13.6M Buy
450,000
+75,000
+20% +$2.17M 0.12% 152
2020
Q1 		$11.2M Buy
+375,000
New +$10.1M 0.12% 159

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Polar Capital's ARQT Position: Q3 2020 in Review

Polar Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 22% in Q3 2020, selling an estimated $2.67M and leaving 350,000 shares worth $10.3M. The position accounts for 0.08% of the portfolio, ranked #181.

Polar Capital first reported a position in ARQT in Q1 2020 and has held it in 3 quarters since. The position peaked at $13.6M in Q2 2020. 63 funds tracked by Wall St. Rank hold ARQT as of Q3 2020.

  • Polar Capital held 350,000 shares of Arcutis Biotherapeutics worth $10.3M as of Q3 2020.
  • Polar Capital sold 100,000 Arcutis Biotherapeutics shares in Q3 2020, an estimated $2.67M.
  • Arcutis Biotherapeutics made up 0.08% of Polar Capital's portfolio in Q3 2020, its #181 holding.
  • Polar Capital first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 3 quarters since.
  • Polar Capital's Arcutis Biotherapeutics position peaked at $13.6M in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.